SAREPTA THERAPEUTICS, INC. Q1 2019 EARNINGS CONFERENCE CALL
FORWARD-LOOKING STATEMENTS

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, priorities and research and development programs including: our plans to advance our PMO and PPMO technologies to treat greater segments of the patient population and bring our RNA platform to new therapeutic diseases; our goal to have the most robust capacity available in gene therapy coupled with the ability to quickly transition constructs from proof-of-concept to commercial process supply; our hiring plans; the potential of having 3 approved therapies by the Q1 2020, representing nearly 30% of the Duchenne population; the potential of PPMO to be a significantly more efficient version of our PMO technology; the potential read through of the results from our first cohort of our LGMD 2E program to other LGMD programs in our pipeline; our hybrid manufacturing strategy and its potential benefits; our belief that we can identify programs that have a high probability of success, that we have the expertise to efficiently move through clinical development and that fit into our commercial portfolio; our expectation to continue our current pace of expansion, maintaining our selective approach around both the science and financial metrics; the expectation to commit some $650M to gene therapy manufacturing over the next 24 months; our plan to deepen the commercial supply relationship with Paragon, including a second dedicated site for Sarepta supply; the potential to profoundly improve the lives of countless patients living with rare disease, build an enduring genetic medicine powerhouse and create enormous shareholder value; our plans re commercial readiness, including educational and genetic testing initiatives, resolving access and reimbursement hurdles and building out our global infrastructure; our estimates re the pricing of life-changing single dose therapies; the expectation that investments in developing our pipeline will grow in 2019 and our plan to internally identify new targets for development; the LGMD2A agreement having a higher probability of success than traditional BD deals; the potential of our pipeline to treat tens of thousands of patients in need and having patients being dosed with gene therapies in Duchenne, LGMD, MPS3A and CMT, as well as have 2 approved RNA therapies for Duchenne in the coming quarters; expected milestones and plans, including having insights on dosing levels for SRP 5051 by the end of 2019 to the first quarter of 2020, completing all dosing in the micro-dystrophin gene therapy trial in Q2 2019 and commencing a multi-center trial with commercial supply by year end, the availability of commercial process supply for the LGMD 2E pivotal study in the first half of 2020, initiating dosing in Cohort 2 at 2E14 in the middle of the year, completing a manufacturing facility with Brammer targeted for commercial manufacturing beginning in late 2019, dosing additional LGMD patients in 2019, reporting out on progress of our first 2E cohort of patients later this year at a medical meeting or a scientific conference, continuing the dosing of our trial for MPS3A, commencing dosing of our first CMT cohort in 2019, obtaining approval for golodirsen and launching golodirsen in 2019, submitting an NDA for casimersen in 2019 with a target approval in the first quarter of 2020, executing our multi-ascending trial for our next generation PPMO in 2019, and finding additional attractive assets to fuel our gene therapy engine.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to EXONDYS 51 sales or attain the net revenues we anticipate for 2019, profitability or positive cash-flow from operations; we may not be able to comply with all FDA post-approval commitments and requirements with respect to EXONDYS 51 in a timely manner or at all; the expected benefits and opportunities related to the agreement with Nationwide Children's pertaining to CAPN-3 may not be realized or may take longer to realize than expected due to challenges and uncertainties inherent in product research and development; Sarepta's dependence on certain manufacturers to produce its product candidates, including any inability on Sarepta's part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; success in preclinical testing and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and initial results from a clinical trial do not necessarily predict final results; our data for golodirsen, casimersen, SRP-9001, the LGMD programs and/or other programs may not be sufficient for obtaining regulatory approval; if the actual number of patients suffering from DMD, LGMDs, pompe disease, CMT and/or MPS IIIA is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; various factors may decrease the market size of our product and product candidates, including the severity of the disease, patient demographics and the response of patients' immune systems to our product candidates; current reimbursement models may not accommodate the unique factors of our gene therapy product candidates; Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of Sarepta's control, including possible limitations of company financial and other resources, manufacturing limitations, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta's product candidates; and those risks identified under the heading "Risk Factors" in Sarepta's most recent Annual Report on Form 10-K for the year ended December 31, 2018 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.